Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16977543 | 0.81 | NISCH (0.43) | CYP3A4CYP2C19CYP17A1CHRM5CHKA | |
| SCHEMBL13612061 | 0.79 | MAPT (0.36) | CYP3A4CYP2C19CYP17A1CHRM5CHKA | |
| SCHEMBL26620718 | 0.77 | SMN1; SMN2 (0.38) | CYP3A4CYP2C19CYP17A1CHRM5MAPT | |
| SCHEMBL8926699 | 0.77 | HTR2A (0.48) | CHRM5SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL119104 | 0.77 | HTR2A (0.48) | CHRM5SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL171013 | 0.77 | HTR2A (0.48) | CHRM5SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL24317333 | 0.76 | KDM4E (0.38) | CYP3A4CYP2C19CYP17A1CHRM5MAPT | |
| Iodide SCHEMBL10962372 | 0.76 | HTR2A (0.46) | CHRM5SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL10436082 | 0.76 | CHRNA7 (0.54) | MAPTALDH1A1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL18378384 | 0.76 | TDP1 (0.50) | SLC6A2SLC6A4SLC6A3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108129431-B | Fluorenonaphthofuran derivative and application thereof | 北京鼎材科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-2670764-B1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8748415-B2 | C-28 amines of C-3 modified betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748415-B2 | C-28 amines of C-3 modified betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130029954-A1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130029954-A1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| EP-1189976-B1 | POLYSILOXANE BLOCK COPOLYMERS IN TOPICAL COSMETIC AND PERSONAL CARE COMPOSITIONS | UNILEVER PLC (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-6365672-B1 | POLYSILOXANE POLYMERS WITH FREE RADICALS | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-04-02 | — | — | US | disclosed |
| EP-1189976-A1 | POLYSILOXANE BLOCK COPOLYMERS IN TOPICAL COSMETIC AND PERSONAL CARE COMPOSITIONS | UNILEVER PLC (GB) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000071607-A1 | POLYSILOXANE BLOCK COPOLYMERS IN TOPICAL COSMETIC AND PERSONAL CARE COMPOSITIONS | UNILEVER PLC (GB) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029954-A1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BET1, ERG28, CD4 | CYP3A4 498/4885CYP2C19 283/4885CYP17A1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.